Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

486P - Genetic polymorphism profile associated with cetuximab efficiency in colorectal cancer patients from Kazakhstan

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Colon and Rectal Cancer

Presenters

Irina Kadyrova

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

I. Kadyrova1, D. Babenko1, S. Kolesnichenko1, Y. Kolesnikova2, A. Turmukhambetova3, L. Akhmaltdinova1, I. Korshukov4, V. Sirota5, V. Zhumaliyeva5, D. Tayzhanova6

Author affiliations

  • 1 Shared Laboratory Of Research And Scientific Center, Karaganda Medical University, 100008 - Karaganda/KZ
  • 2 Department Of Biochemistry, Karaganda Medical University, 100008 - Karaganda/KZ
  • 3 Administration, Karaganda Medical University, 100008 - Karaganda/KZ
  • 4 Department Of Computer Science And Biostatistics, Karaganda Medical University, 100008 - Karaganda/KZ
  • 5 Department Of Oncology, Karaganda Medical University, 100008 - Karaganda/KZ
  • 6 Department Of Internal Diseases, Karaganda Medical University, 100008 - Karaganda/KZ

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 486P

Background

Colorectal cancer (CRC) is one of the leading causes of mortality from cancer. Cetuximab is a chimeric antibody inhibiting the epidermal growth receptor (EGFR) and has been demonstrated to be effective to treat CRC. However, there are number of single nucleotide polymorphisms (SNPs) leading to a change in the effectiveness of cetuximab treatment. The aim of this study was to investigate SNPs associated with cetuximab efficiency in a Kazakhstan population.

Methods

Genotyping of 9 SNPs associated with cetuximab efficiency (located in 7 different genes on 5 different chromosomes) was performed by QuantStudio 12K Flex PCR and analysed with Thermo Fisher Scientific Cloud service. Statistical analysis was performed with web source [https://www.snpstats.net/]. Log-additive and codominant inheritance models were used for identifying associations.

Results

243 patients with CRC aged from 24 to 87 (female =110; male = 133) and 71 persons from control group, comparable by age and gender, were analysed. Chi-square criteria for SNPs minor allele frequencies (MAF) were calculated. One polymorphism demonstrated significant results (rs2227983 (G/A)) (P=0.02). For rs2227983, MAF was detected in 44% of the control group and 33% of the CRC group. MAF for rs2227983 in Kazakhstan population is nearest to the Southern Asians (35%), while East Asians demonstrate 52% of MAF in this SNP. The MAF for this polymorphism is 29% in the total population. SIFT and PolyPhen predictive models determined rs2227983 as benign. However, PharmGKB indicates that patients with the AA genotype may have decreased survival when treated with cetuximab when compared to patients with the GG genotype. Rs2227983 is located on Chromosome 7:55161562 in the EGRF gene and is involved in PI3K/AKT signalling, so it would be appropriate to consider its inheritance models. According to log-additive genetic modelling of inheritance we found that rs2227983 had a significant association with cetuximab efficiency (P = 0.016) and showed a highly significant inheritance codominant model with odds ratio (OR) 3.55 (P= 0.018).

Conclusions

One polymorphism (rs2227983) was found to be significantly different between cohorts. In the future, cetuximab efficiency should be further explored in the Kazakhstan population in CRC patients including additional influencing factors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Karaganda Medical University.

Funding

Ministry of Education and Science of the Republic of Kazakhstan (Research project # BR05236771).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.